In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation, as amended and supplemented, the Competition Council makes available to the public the below “operation summary” containing the information provided by the parties.<\/p>\n
This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation.<\/p>\n
The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law No. 104-12 on freedom of prices and competition as amended and supplemented.<\/p>\n
Names of the companies and groups involved:<\/strong><\/p>\n Nature of the operation<\/strong><\/p>\n Economic sectors concerned<\/strong><\/p>\n Deadline for interested third parties to submit their observations<\/strong><\/p>\n NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES<\/strong><\/p>\n The Competition Council received notification of an economic concentration operation concerning the acquisition by the company \u201cThe Carlyle Group Inc.\u201d, through the company \u201cCP Spruce Holdings, SCSp\u201d, of the indirect exclusive control of the renal care segment of the company \u201cBaxter International Inc.\u201d, known as \u201cVantive\u201d.<\/p>\n \u201cThe Carlyle Group Inc.<\/em>\u201d is a US company active in alternative asset management and managing funds that invest internationally in three investment disciplines: (i) private equity (including corporate private equity, real estate, and natural resources private equity); (ii) credit (including liquid credit, illiquid credit, and real asset credit); and (iii) investment solutions (private equity fund program, which includes primary funds, secondary funds, and corresponding co-investment activities).<\/p>\n \u201cCP Spruce Holdings, SCSp<\/em>\u201d is a Luxembourg special limited partnership established for the purpose of carrying out the operation.<\/p>\n \u201cVantive<\/em>\u201d is the renal care segment of \u201cBaxter International Inc.<\/em>\u201d, a US company. It is primarily engaged in the supply of renal replacement therapy (RRT) products. RRT products are used to treat patients with renal failure.<\/p>\n <\/p>\n Done in Rabat on October 10, 2024<\/p>\n","protected":false},"excerpt":{"rendered":" In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation, as amended and supplemented, the Competition Council makes available to the public the below “operation summary” containing the information provided by the parties. This information has been prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation. The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law No. 104-12 on freedom of prices and competition as amended and supplemented. Names of the companies and groups involved: The indirect acquirer: The company \u201cThe Carlyle Group Inc.\u201d; The direct acquirer: The company \u201cCP Spruce Holdings, SCSp\u201d; The target: The renal care segment of the company \u201cBaxter International Inc.\u201d, known as \u201cVantive\u201d. Nature of the operation Acquisition of exclusive control. Economic sectors concerned Sector of the supply of renal replacement therapy (RRT) products Deadline for interested third parties to submit their observations 10 days from the date of publication of this press release, i.e., October 21, 2024. NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES The Competition Council received notification of an economic concentration operation concerning the acquisition by the company \u201cThe Carlyle Group Inc.\u201d, through the company \u201cCP Spruce Holdings, SCSp\u201d, of the indirect exclusive control of the renal care segment of the company \u201cBaxter International Inc.\u201d, known as \u201cVantive\u201d. \u201cThe Carlyle Group Inc.\u201d is a US company active in alternative asset management and managing funds that invest internationally in three investment disciplines: (i) private equity (including corporate private equity, real estate, and natural resources private equity); (ii) credit (including liquid credit, illiquid credit, and real asset credit); and (iii) investment solutions (private equity fund program, which includes primary funds, secondary funds, and corresponding co-investment activities). \u201cCP Spruce Holdings, SCSp\u201d is a Luxembourg special limited partnership established for the purpose of carrying out the operation. \u201cVantive\u201d is the renal care segment of \u201cBaxter International Inc.\u201d, a US company. It is primarily engaged in the supply of renal replacement therapy (RRT) products. RRT products are used to treat patients with renal failure. Done in Rabat on October 10, 2024<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[352],"tags":[],"class_list":["post-40563","post","type-post","status-publish","format-standard","hentry","category-press-releases"],"acf":[],"yoast_head":"\n\n
\n
\n
\n